EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

Richard J. Davis, Colin E. Murdoch, Mozam Ali, Stuart Purbrick, Rivka Ravid, Gordon S. Baxter, Nick Tilford, Robert L.G. Sheldrick, Kenneth L. Clark, Robert A. Coleman

Research output: Contribution to journalArticle

Abstract

1 Dilatation of the cerebral vasculature is recognised to be involved in the pathophysiology of migraine. Furthermore, elevated levels of prostaglandin E2 (PGE2) occur in the blood, plasma and saliva of migraineurs during an attack, suggestive of a contributory role. In the present study, we have characterised the prostanoid receptors involved in the relaxation and contraction of human middle cerebral arteries in vitro. 2 In the presence of indomethacin (3μM) and the TP receptor antagonist GR32191 (1 μM), PGE2 was found to relax phenylephrine precontracted cerebral arterial rings in a concentration-dependent manner (mean pEC50 8.0 ± 0.1, n = 5). 3 Establishment of a rank order of potency using the EP4 > EP2 agonist 11-deoxy PGE1, and the EP2 > EP4 agonist PGE1-OH (mean pEC 50 of 7.6 ± 0.1 (n = 6) and 6.4 ± 0.1 (n = 4), respectively), suggested the presence of functional EP4 receptors. Furthermore, the selective EP2 receptor agonist butaprost at concentrations < 1 μM failed to relax the tissues. 4 Blockade of EP 4 receptors with the EP4 receptor antagonists AH23848 and EP4A caused significant rightward displacements in PGE2 concentration-response curves, exhibiting pA2 and pKB values of 5.7 ± 0.1, n = 3, and 8.4, n = 3, respectively. 5 The IP receptor agonists iloprost and cicaprost relaxed phenylephrine precontracted cerebral arterial rings (mean pEC50 values 8.3 ± 0.1 (n = 4) and 8.1 ± 0.1 (n = 9), respectively). In contrast, the DP and FP receptor agonists PGD2 and PGFα2 failed to cause appreciable relaxation or contraction at concentrations of up to 30 μM. In the absence of phenylephrine contraction and GR32191, the TP receptor agonist U46619 caused concentration-dependent contraction of cerebral artery (mean pEC50 7.4 ± 0.3, n = 3). 6 These data demonstrate the presence of prostanoid EP4 receptors mediating PGE2 vasodilatation of human middle cerebral artery. IP receptors mediating relaxation and TP receptors mediating contraction were also functionally demonstrated.

Original languageEnglish
Pages (from-to)580-585
Number of pages6
JournalBritish Journal of Pharmacology
Volume141
Issue number4
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Receptors, Prostaglandin E, EP4 Subtype
Middle Cerebral Artery
Thromboxane Receptors
Dinoprostone
Vasodilation
Phenylephrine
Iloprost
Prostaglandin D2
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Dinoprost
Cerebral Arteries
Alprostadil
Migraine Disorders
Saliva
Indomethacin
Prostaglandins
Dilatation

Keywords

  • EP4 receptor
  • human middle cerebral artery
  • migraine
  • prostaglandin E2

Cite this

Davis, R. J., Murdoch, C. E., Ali, M., Purbrick, S., Ravid, R., Baxter, G. S., ... Coleman, R. A. (2004). EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. British Journal of Pharmacology, 141(4), 580-585. https://doi.org/10.1038/sj.bjp.0705645
Davis, Richard J. ; Murdoch, Colin E. ; Ali, Mozam ; Purbrick, Stuart ; Ravid, Rivka ; Baxter, Gordon S. ; Tilford, Nick ; Sheldrick, Robert L.G. ; Clark, Kenneth L. ; Coleman, Robert A. / EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. In: British Journal of Pharmacology. 2004 ; Vol. 141, No. 4. pp. 580-585.
@article{d1737770b7e04b5e8aa90655fc7cf041,
title = "EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries",
abstract = "1 Dilatation of the cerebral vasculature is recognised to be involved in the pathophysiology of migraine. Furthermore, elevated levels of prostaglandin E2 (PGE2) occur in the blood, plasma and saliva of migraineurs during an attack, suggestive of a contributory role. In the present study, we have characterised the prostanoid receptors involved in the relaxation and contraction of human middle cerebral arteries in vitro. 2 In the presence of indomethacin (3μM) and the TP receptor antagonist GR32191 (1 μM), PGE2 was found to relax phenylephrine precontracted cerebral arterial rings in a concentration-dependent manner (mean pEC50 8.0 ± 0.1, n = 5). 3 Establishment of a rank order of potency using the EP4 > EP2 agonist 11-deoxy PGE1, and the EP2 > EP4 agonist PGE1-OH (mean pEC 50 of 7.6 ± 0.1 (n = 6) and 6.4 ± 0.1 (n = 4), respectively), suggested the presence of functional EP4 receptors. Furthermore, the selective EP2 receptor agonist butaprost at concentrations < 1 μM failed to relax the tissues. 4 Blockade of EP 4 receptors with the EP4 receptor antagonists AH23848 and EP4A caused significant rightward displacements in PGE2 concentration-response curves, exhibiting pA2 and pKB values of 5.7 ± 0.1, n = 3, and 8.4, n = 3, respectively. 5 The IP receptor agonists iloprost and cicaprost relaxed phenylephrine precontracted cerebral arterial rings (mean pEC50 values 8.3 ± 0.1 (n = 4) and 8.1 ± 0.1 (n = 9), respectively). In contrast, the DP and FP receptor agonists PGD2 and PGFα2 failed to cause appreciable relaxation or contraction at concentrations of up to 30 μM. In the absence of phenylephrine contraction and GR32191, the TP receptor agonist U46619 caused concentration-dependent contraction of cerebral artery (mean pEC50 7.4 ± 0.3, n = 3). 6 These data demonstrate the presence of prostanoid EP4 receptors mediating PGE2 vasodilatation of human middle cerebral artery. IP receptors mediating relaxation and TP receptors mediating contraction were also functionally demonstrated.",
keywords = "EP4 receptor, human middle cerebral artery, migraine, prostaglandin E2",
author = "Davis, {Richard J.} and Murdoch, {Colin E.} and Mozam Ali and Stuart Purbrick and Rivka Ravid and Baxter, {Gordon S.} and Nick Tilford and Sheldrick, {Robert L.G.} and Clark, {Kenneth L.} and Coleman, {Robert A.}",
year = "2004",
month = "2",
doi = "10.1038/sj.bjp.0705645",
language = "English",
volume = "141",
pages = "580--585",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

Davis, RJ, Murdoch, CE, Ali, M, Purbrick, S, Ravid, R, Baxter, GS, Tilford, N, Sheldrick, RLG, Clark, KL & Coleman, RA 2004, 'EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries', British Journal of Pharmacology, vol. 141, no. 4, pp. 580-585. https://doi.org/10.1038/sj.bjp.0705645

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. / Davis, Richard J.; Murdoch, Colin E.; Ali, Mozam; Purbrick, Stuart; Ravid, Rivka; Baxter, Gordon S.; Tilford, Nick; Sheldrick, Robert L.G.; Clark, Kenneth L.; Coleman, Robert A.

In: British Journal of Pharmacology, Vol. 141, No. 4, 02.2004, p. 580-585.

Research output: Contribution to journalArticle

TY - JOUR

T1 - EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

AU - Davis, Richard J.

AU - Murdoch, Colin E.

AU - Ali, Mozam

AU - Purbrick, Stuart

AU - Ravid, Rivka

AU - Baxter, Gordon S.

AU - Tilford, Nick

AU - Sheldrick, Robert L.G.

AU - Clark, Kenneth L.

AU - Coleman, Robert A.

PY - 2004/2

Y1 - 2004/2

N2 - 1 Dilatation of the cerebral vasculature is recognised to be involved in the pathophysiology of migraine. Furthermore, elevated levels of prostaglandin E2 (PGE2) occur in the blood, plasma and saliva of migraineurs during an attack, suggestive of a contributory role. In the present study, we have characterised the prostanoid receptors involved in the relaxation and contraction of human middle cerebral arteries in vitro. 2 In the presence of indomethacin (3μM) and the TP receptor antagonist GR32191 (1 μM), PGE2 was found to relax phenylephrine precontracted cerebral arterial rings in a concentration-dependent manner (mean pEC50 8.0 ± 0.1, n = 5). 3 Establishment of a rank order of potency using the EP4 > EP2 agonist 11-deoxy PGE1, and the EP2 > EP4 agonist PGE1-OH (mean pEC 50 of 7.6 ± 0.1 (n = 6) and 6.4 ± 0.1 (n = 4), respectively), suggested the presence of functional EP4 receptors. Furthermore, the selective EP2 receptor agonist butaprost at concentrations < 1 μM failed to relax the tissues. 4 Blockade of EP 4 receptors with the EP4 receptor antagonists AH23848 and EP4A caused significant rightward displacements in PGE2 concentration-response curves, exhibiting pA2 and pKB values of 5.7 ± 0.1, n = 3, and 8.4, n = 3, respectively. 5 The IP receptor agonists iloprost and cicaprost relaxed phenylephrine precontracted cerebral arterial rings (mean pEC50 values 8.3 ± 0.1 (n = 4) and 8.1 ± 0.1 (n = 9), respectively). In contrast, the DP and FP receptor agonists PGD2 and PGFα2 failed to cause appreciable relaxation or contraction at concentrations of up to 30 μM. In the absence of phenylephrine contraction and GR32191, the TP receptor agonist U46619 caused concentration-dependent contraction of cerebral artery (mean pEC50 7.4 ± 0.3, n = 3). 6 These data demonstrate the presence of prostanoid EP4 receptors mediating PGE2 vasodilatation of human middle cerebral artery. IP receptors mediating relaxation and TP receptors mediating contraction were also functionally demonstrated.

AB - 1 Dilatation of the cerebral vasculature is recognised to be involved in the pathophysiology of migraine. Furthermore, elevated levels of prostaglandin E2 (PGE2) occur in the blood, plasma and saliva of migraineurs during an attack, suggestive of a contributory role. In the present study, we have characterised the prostanoid receptors involved in the relaxation and contraction of human middle cerebral arteries in vitro. 2 In the presence of indomethacin (3μM) and the TP receptor antagonist GR32191 (1 μM), PGE2 was found to relax phenylephrine precontracted cerebral arterial rings in a concentration-dependent manner (mean pEC50 8.0 ± 0.1, n = 5). 3 Establishment of a rank order of potency using the EP4 > EP2 agonist 11-deoxy PGE1, and the EP2 > EP4 agonist PGE1-OH (mean pEC 50 of 7.6 ± 0.1 (n = 6) and 6.4 ± 0.1 (n = 4), respectively), suggested the presence of functional EP4 receptors. Furthermore, the selective EP2 receptor agonist butaprost at concentrations < 1 μM failed to relax the tissues. 4 Blockade of EP 4 receptors with the EP4 receptor antagonists AH23848 and EP4A caused significant rightward displacements in PGE2 concentration-response curves, exhibiting pA2 and pKB values of 5.7 ± 0.1, n = 3, and 8.4, n = 3, respectively. 5 The IP receptor agonists iloprost and cicaprost relaxed phenylephrine precontracted cerebral arterial rings (mean pEC50 values 8.3 ± 0.1 (n = 4) and 8.1 ± 0.1 (n = 9), respectively). In contrast, the DP and FP receptor agonists PGD2 and PGFα2 failed to cause appreciable relaxation or contraction at concentrations of up to 30 μM. In the absence of phenylephrine contraction and GR32191, the TP receptor agonist U46619 caused concentration-dependent contraction of cerebral artery (mean pEC50 7.4 ± 0.3, n = 3). 6 These data demonstrate the presence of prostanoid EP4 receptors mediating PGE2 vasodilatation of human middle cerebral artery. IP receptors mediating relaxation and TP receptors mediating contraction were also functionally demonstrated.

KW - EP4 receptor

KW - human middle cerebral artery

KW - migraine

KW - prostaglandin E2

UR - http://www.scopus.com/inward/record.url?scp=4944238567&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0705645/abstract

U2 - 10.1038/sj.bjp.0705645

DO - 10.1038/sj.bjp.0705645

M3 - Article

AN - SCOPUS:4944238567

VL - 141

SP - 580

EP - 585

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -